Brain targeted nanoparticle for Alzheimer's disease therapy

用于治疗阿尔茨海默病的脑靶向纳米颗粒

基本信息

  • 批准号:
    9329544
  • 负责人:
  • 金额:
    $ 36.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-03-01 至 2022-02-28
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Alzheimer’s disease (AD), which consumed ~$226 billion in health care costs in 2015, is associated with nervous system chronic inflammation. Recent research revealed that the malfunction of microglia is critical for the development of AD. Our preliminary study developed a dual targeted dual responsive nanoparticle (DTDRN) which can effectively penetrate the blood brain barrier (BBB) and release its payload in the brain. Furthermore, N-acetyl cysteine (NAC)-loaded DTDRN showed much better therapeutic effect than free NAC in a LPS-induced brain inflammatory animal model. The objective of this study is to develop a brain targeted system for AD therapy by rationally utilizing the characteristics of both BBB and the brain tissue. In Aim 1, we will develop a NAC-DTDRN and characterize its BBB penetration efficiency in vitro. Aim 2 will evaluate the anti-inflammatory and anti-oxidant effects of the NAC-DTDRN in vitro and study its pharmacokinetics in vivo. Aim 3 will test the efficiency of the NAC-DTDRN in an AD animal model and evaluate its toxicity. In summary, NAC delivery via the proposed DTDRN system which can effectively penetrate the BBB and exhibit anti- inflammatory effects has potential to benefit AD patients. Due to the versatility of DTDRN, the proposed DTDRN system can carry other therapeutic molecules (both hydrophobic and hydrophilic) to the brain and to be applied for the detection and treatment of other central nervous system diseases such as Parkinson disease, traumatic brain injury, and multiple sclerosis.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Peisheng Xu其他文献

Peisheng Xu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Peisheng Xu', 18)}}的其他基金

Cancer cell selective killing nanoparticle for advanced ovarian cancer treatment
癌细胞选择性杀伤纳米颗粒用于晚期卵巢癌治疗
  • 批准号:
    10680585
  • 财政年份:
    2022
  • 资助金额:
    $ 36.63万
  • 项目类别:
Cancer cell selective killing nanoparticle for advanced ovarian cancer treatment
癌细胞选择性杀伤纳米颗粒用于晚期卵巢癌治疗
  • 批准号:
    10453919
  • 财政年份:
    2022
  • 资助金额:
    $ 36.63万
  • 项目类别:
The development of a multifunctional nanoenzyme for AD treatment
用于AD治疗的多功能纳米酶的开发
  • 批准号:
    10611675
  • 财政年份:
    2022
  • 资助金额:
    $ 36.63万
  • 项目类别:
Nano-cocktail overcomes multidrug-resistance for ovarian cancer therapy
纳米鸡尾酒克服了卵巢癌治疗的多重耐药性
  • 批准号:
    8958102
  • 财政年份:
    2015
  • 资助金额:
    $ 36.63万
  • 项目类别:
Dual responsive nanoparticle for brain targeted drug delivery
用于大脑靶向药物输送的双响应纳米颗粒
  • 批准号:
    8653312
  • 财政年份:
  • 资助金额:
    $ 36.63万
  • 项目类别:
Dual responsive nanoparticle for brain targeted drug delivery
用于大脑靶向药物输送的双响应纳米颗粒
  • 批准号:
    8885856
  • 财政年份:
  • 资助金额:
    $ 36.63万
  • 项目类别:
Dual responsive nanoparticle for brain targeted drug delivery
用于大脑靶向药物输送的双响应纳米颗粒
  • 批准号:
    9061734
  • 财政年份:
  • 资助金额:
    $ 36.63万
  • 项目类别:

相似海外基金

The Role of Arginine Transport on Pancreatic Alpha Cell Proliferation and Function
精氨酸转运对胰腺α细胞增殖和功能的作用
  • 批准号:
    10678248
  • 财政年份:
    2023
  • 资助金额:
    $ 36.63万
  • 项目类别:
Alpha cell-derived Extracellular Vesicles and Maternal Insulin Production
α细胞来源的细胞外囊泡和母体胰岛素的产生
  • 批准号:
    10681939
  • 财政年份:
    2023
  • 资助金额:
    $ 36.63万
  • 项目类别:
Targeting alpha-cell GPCRs to stimulate glucagon and counter hypoglycemia
靶向 α 细胞 GPCR 刺激胰高血糖素并对抗低血糖
  • 批准号:
    10427574
  • 财政年份:
    2022
  • 资助金额:
    $ 36.63万
  • 项目类别:
Arginine regulation of alpha cell proliferation and function
精氨酸调节α细胞增殖和功能
  • 批准号:
    10609909
  • 财政年份:
    2022
  • 资助金额:
    $ 36.63万
  • 项目类别:
Regulation of alpha-cell glucagon secretion by mitochondrial anaplerosis-cataplerosis
线粒体回补-回补对α细胞胰高血糖素分泌的调节
  • 批准号:
    10607392
  • 财政年份:
    2022
  • 资助金额:
    $ 36.63万
  • 项目类别:
Targeting alpha-cell GPCRs to stimulate glucagon and counter hypoglycemia
靶向 α 细胞 GPCR 刺激胰高血糖素并对抗低血糖
  • 批准号:
    10675646
  • 财政年份:
    2022
  • 资助金额:
    $ 36.63万
  • 项目类别:
Elucidating alpha cell defects in human type 1 diabetes using precision cut pancreas slice-on-a-chip coupled with high spatio-temporal microscopy
使用精密切割的胰腺切片结合高时空显微镜阐明人类 1 型糖尿病的 α 细胞缺陷
  • 批准号:
    457552
  • 财政年份:
    2021
  • 资助金额:
    $ 36.63万
  • 项目类别:
    Studentship Programs
Defining alpha-cell proglucagon processing for type 2 diabetes treatment
定义 2 型糖尿病治疗的 α 细胞胰高血糖素原加工过程
  • 批准号:
    10331361
  • 财政年份:
    2020
  • 资助金额:
    $ 36.63万
  • 项目类别:
In vivo systems to discover mechanisms regulating human islet alpha cell function
体内系统发现调节人类胰岛α细胞功能的机制
  • 批准号:
    10623306
  • 财政年份:
    2020
  • 资助金额:
    $ 36.63万
  • 项目类别:
Defining alpha-cell PC1/3 expression regulation for type 2 diabetes
定义 2 型糖尿病的 α 细胞 PC1/3 表达调控
  • 批准号:
    10376866
  • 财政年份:
    2020
  • 资助金额:
    $ 36.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了